Close menu

October 17th, 2022 | 12:21 CEST

Defence Therapeutics, Commerzbank - Like BioNTech in March 2020?

  • Biotechnology
  • Turnaround
Photo credits:

After price shocks and recession fears, the pandemic has also been back in the public eye since last week. German Health Minister Karl Lauterbach presented the vaccination strategy for the fall - and warned of an autumn wave. On the markets, the pandemic should be over, with a few exceptions. But Corona and BioNTech are suitable blueprints for other companies. We explain where else a special boom could occur and where investors are better off being cautious.

time to read: 4 minutes | Author: Nico Popp

Table of contents:

    BioNTech: Between vaccine strategy and cancer fantasy

    As share prices worldwide plummeted in March 2020, the strategists behind BioNTech were working on the Company's future. Despite the general doom and gloom, a huge opportunity opened up for BioNTech. The mRNA technology they had long been researching was suddenly in demand like never before. The desire for fast and effective vaccines was great. In the US, then-US President Donald Trump made possibly the best decision of his time in office: he declared the search for a vaccine the country's most important mission - no matter what the cost. Because of this support, Pfizer and BioNTech were able to develop their Corona vaccine quickly. Where the typical process involves pausing and gradually injecting capital depending on details, Pfizer and BioNTech have been able to draw on their full resources.

    In Germany, another vaccination campaign is currently underway. People over 60 and those with previous illnesses can get their 4th shot. Vaccines have now been developed expressly for the Omicron variant. This new demand for vaccines should have a positive impact on BioNTech. However, the great vaccination hype is over. Shareholders can still rejoice: BioNTech recently opened a subsidiary in Australia, where it plans to conduct more research into vaccines against cancer. The cash flow from the Corona vaccines will therefore be invested for growth. The share has stabilized in recent months and could rise again in the medium term. However, BioNTech is no longer an insider tip.

    Defence Therapeutics facing months of truth

    The situation is quite different for the Canadian company Defence Therapeutics. The biotech company has a broad range of active ingredients and active ingredient enhancers that can be used in various ways. They recently announced a clinical trial for the active ingredient AccuTOX™ to fight lung cancer. What is unique about the pre-clinical study is that the compound will be administered intranasally to then act in the lungs. The active ingredient AccuTOX™, for which Defence Therapeutics has filed a patent application, is an offshoot of the Accum™ technology, which has been known for some time. In short, the aim is to channel various active ingredients more effectively into the cell nucleus and thus achieve greater effects. Defence Therapeutics is using this process to research vaccines against various cancer types, including skin and cervical cancer. Clinical trials are scheduled to start in early 2023.

    Since Accum™ can be used very flexibly as a drug booster, it is also conceivable that the technology will help other active ingredients that have already been discarded in clinical trials to make a comeback. The first phase of clinical trials is all about the safety of active ingredients. If this is not the case, the trial fails. If the dose can be drastically reduced thanks to active ingredient boosters, previously failed projects could be given a new lease of life. Investors can also recognize "fresh blood" when they look at the performance of the Defence Therapeutics share. The value has recovered recently but is still cheap. It will be crucial for the Company to be able to implement its plans. Given the versatility of the technology and the numerous opportunities, knowledgeable investors should already have the Company on their radar. Defence Therapeutics is currently comparable to BioNTech before COVID-19 was declared a pandemic - only industry insiders have the value on their radar. However, this should change as soon as scientific perspectives turn into concrete market opportunities. The stock is speculative but also about 80% cheaper than a year ago. In addition, operational progress is imminent. Defence Therapeutics is anything but uninteresting!

    Commerzbank: Interest rate turnaround positive, real estate market negative!

    The same applies to the Commerzbank share. The Frankfurt share price has remained stable in recent weeks despite the challenging market environment. As we recall, at times, there was even talk of a new banking quake. However, these speculations have left the yellow bank cold. However, trouble is looming in the real estate business. As Savings Bank President Helmut Schleweis told the Handelsblatt, many real estate projects in the planning stage are currently being put on hold again. Also, many private prospective customers simply could not afford real estate any longer - the mortgage interest multiplied in 2022. At the same time, inflation and a shortage of materials are weighing on construction and renovation. Commerzbank recently benefited from the bear market rally. However, many construction sites still remain. Between EUR 8.20 and EUR 8.40, the share must show what it can do. If the breakout above this level fails, it can also go down again.

    Even though many banks have been eagerly awaiting the turnaround in interest rates, higher interest rates are anything but a special boom. The distortions in the current situation are too great. On the other hand, stocks that can do well in any market are BioNTech or even Defence Therapeutics. Whoever develops the next blockbuster is guaranteed to leave inflation and crisis behind. While BioNTech is already an old hand in the business, Defence Therapeutics still has the aura of a newcomer. In addition, there are the many projects and the opportunity for licensing income if, for example, the patented active ingredient enhancer were to be made available to other companies. The coming months are likely to be exciting.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author

    Related comments:

    Commented by Juliane Zielonka on September 29th, 2023 | 07:00 CEST

    Defence Therapeutics, Schott Pharma, Allianz Group: Focus on Innovation, Growth and Portfolio Optimization

    • Biotechnology
    • Pharma
    • Investments

    According to a recent study, biotech company Defence Therapeutics achieves twice the immune response of conventional mRNA therapies with its Accum® mRNA technology. That translates to fewer side effects and a more effective treatment. According to Precedence Research, the market size for mRNA therapeutics is projected to reach approximately USD 137.59 billion by 2032. It is expected to grow at a CAGR of 13.2% from 2023 to 2032. In order to inject these active ingredients, precision-fit medical vials are required, and Schott Pharma is ensuring this with their IPO launched on the German stock exchange this week, which could bring a valuation of around EUR 4 billion. The Allianz Group, on the other hand, is focusing on consolidation, selling its business in the Middle East and thus flushing around EUR 210 million cash into its coffers.


    Commented by Nico Popp on September 27th, 2023 | 07:10 CEST

    Rich as a Sheikh? Here is what's happening: Schott Pharma, BioNTech, Cardiol Therapeutics

    • Biotechnology
    • Pharma

    High-tech or add-on? When Schott Pharma's shares go public in Frankfurt on Thursday, investors are likely to have a clear opinion. The manufacturer of pharmaceutical packaging may be attracting significant interest precisely because its business model is clearly defined. But what sets Schott apart, and which companies in the pharmaceutical and biotech industry might also become interesting? We provide insights and deliver answers!


    Commented by Juliane Zielonka on September 22nd, 2023 | 06:50 CEST

    Cardiol Therapeutics, BioNTech, BYD - At top speed to new markets

    • Biotechnology
    • Pharma
    • Electromobility

    Cardiol Therapeutics is enjoying a remarkable development. The biotech company is now rolling out its ARCHER patient recruitment trial internationally at 35 participating centers. This accelerates research in the development of their therapy to combat myocarditis, a heart inflammation which has been associated with COVID-19 vaccination. For Cardiol Therapeutics, this represents an opportunity to get its therapy approved as an orphan drug. Approval is also at stake for BioNTech. With a multimillion-dollar funding boost, the Company is working on accelerated approval for a vaccine against a virus that caused quite a stir last year. The shortened development time is likely to impress investors. While business nations agree on fighting viruses, they disagree on commodities for the road. The EU would prefer to restrict BYD's successful sales on domestic roads - by imposing tariffs. BYD, meanwhile, is tapping into a completely different market.